-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ARK Investment Management LLC Increases Position in RedHill Biopharma Ltd. (NASDAQ:RDHL)
ARK Investment Management LLC Increases Position in RedHill Biopharma Ltd. (NASDAQ:RDHL)
ARK Investment Management LLC grew its holdings in RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) by 21.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,045,023 shares of the biotechnology company's stock after acquiring an additional 183,225 shares during the quarter. ARK Investment Management LLC's holdings in RedHill Biopharma were worth $1,170,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in RDHL. HighTower Advisors LLC purchased a new position in RedHill Biopharma during the fourth quarter worth about $32,000. GSA Capital Partners LLP raised its holdings in RedHill Biopharma by 108.4% during the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. Gagnon Securities LLC raised its holdings in RedHill Biopharma by 15.4% during the first quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. BlackRock Inc. raised its holdings in RedHill Biopharma by 18.6% during the first quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after purchasing an additional 56,178 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its holdings in RedHill Biopharma by 0.7% during the first quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock worth $4,914,000 after purchasing an additional 14,413 shares in the last quarter. 7.74% of the stock is owned by hedge funds and other institutional investors.
Get RedHill Biopharma alerts:RedHill Biopharma Stock Down 7.5 %
NASDAQ RDHL opened at $0.68 on Tuesday. RedHill Biopharma Ltd. has a 52-week low of $0.62 and a 52-week high of $6.50. The firm has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.32. The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79.
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last posted its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The firm had revenue of $18.24 million during the quarter. During the same period in the prior year, the company earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.83 earnings per share for the current fiscal year.RedHill Biopharma Company Profile
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Featured Stories
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating).
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
ARK Investment Management LLC grew its holdings in RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) by 21.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,045,023 shares of the biotechnology company's stock after acquiring an additional 183,225 shares during the quarter. ARK Investment Management LLC's holdings in RedHill Biopharma were worth $1,170,000 as of its most recent filing with the SEC.
据Holdings Channel.com报道，方舟投资管理有限公司在第二季度增持了红山生物制药有限公司(纳斯达克代码：RDHL-GET评级)21.3%的股份。该机构投资者在本季度增持了183,225股后，持有这家生物技术公司的1,045,023股股票。截至最近向美国证券交易委员会提交的文件，方舟投资管理公司持有的红山生物医药股份价值117万美元。
A number of other institutional investors and hedge funds have also made changes to their positions in RDHL. HighTower Advisors LLC purchased a new position in RedHill Biopharma during the fourth quarter worth about $32,000. GSA Capital Partners LLP raised its holdings in RedHill Biopharma by 108.4% during the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. Gagnon Securities LLC raised its holdings in RedHill Biopharma by 15.4% during the first quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. BlackRock Inc. raised its holdings in RedHill Biopharma by 18.6% during the first quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after purchasing an additional 56,178 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its holdings in RedHill Biopharma by 0.7% during the first quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock worth $4,914,000 after purchasing an additional 14,413 shares in the last quarter. 7.74% of the stock is owned by hedge funds and other institutional investors.
其他一些机构投资者和对冲基金也改变了他们在RDHL的头寸。HighTower Advisors LLC在第四季度购买了RedHill Biophma的一个新头寸，价值约3.2万美元。GSA Capital Partners LLP在第四季度增持了108.4%的红山生物科技股份。GSA Capital Partners LLP现在持有这家生物技术公司218,338股股票，价值563,000美元，上个季度又购买了113,584股。Gagnon Securities LLC在第一季度将其在RedHill Biophma的持股增加了15.4%。Gagnon Securities LLC现在拥有这家生物技术公司367,346股股票，价值926,000美元，上个季度又购买了49,023股。贝莱德股份有限公司在第一季度增持红山生物科技18.6%的股份。贝莱德股份有限公司目前持有这家生物技术公司357,493股股票，价值901,000美元，该公司在上个季度又购买了56,178股。最后，Ceduled Growth Investors Inc.在第一季度将其在RedHill Biophma的持股增加了0.7%。在上个季度增持了14,413股后，Acciated Growth Investors Inc.现在持有1,950,002股这家生物技术公司的股票，价值4,914,000美元。7.74%的股票由对冲基金和其他机构投资者持有。
RedHill Biopharma Stock Down 7.5 %
红山Biophma股价下跌7.5%
NASDAQ RDHL opened at $0.68 on Tuesday. RedHill Biopharma Ltd. has a 52-week low of $0.62 and a 52-week high of $6.50. The firm has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.32. The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79.
纳斯达克rdhl周二开盘报0.68美元。RedHill Biophma Ltd.股价跌至0.62美元的52周低点和6.50美元的52周高点。该公司的50日移动均线价格为0.92美元，200日移动均线价格为1.32美元。该公司的债务权益比为9.42，流动比率为0.98，速动比率为0.79。
RedHill Biopharma Company Profile
红山生物医药公司简介
(Get Rating)
(获取评级)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
红山生物制药有限公司是一家专业的生物制药公司，主要专注于胃肠道和传染病。该公司推广胃肠药物，包括用于治疗患有慢性非癌症疼痛的成人阿片类药物引起的便秘的Movantik；用于治疗成人幽门螺杆菌感染的Talicia；以及用于治疗成人旅行者腹泻的Aemcolo。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免费获取StockNews.com关于RedHill Biophma(RDHL)的研究报告
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它：投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗？
- 自动区重新进入拉力赛模式，新高在望
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating).
想看看还有哪些对冲基金持有RDHL吗？访问HoldingsChannel.com获取红山生物医药有限公司(纳斯达克代码：Rdhl-Get Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《红山生物报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对RedHill Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧